10-Q: Profusa Inc. Faces Financial Hurdles Amidst Strategic Moves

Profusa, Inc. reports Q3 2026 results, highlighting operational cost reductions and strategic financing efforts, but continues to face substantial going concern risks and significant net losses.

Summary

• Profusa, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026.
• The company reported a net loss of $17.2 million for the nine months ended September 30, 2026, compared to a net loss of $31.2 million for the same period in 2025.
• Operating expenses decreased significantly, with Research and Development expenses down 69% and General and Administrative expenses down 78% for the three months ended September 30, 2026, compared to the prior year.
• The company continues to face substantial doubt about its ability to continue as a going concern, with a working capital deficit of $20.7 million as of September 30, 2026.
• Profusa has been actively engaged in various financing activities, including amendments to PIPE notes and exchange agreements to settle outstanding debt.
• The company announced receiving ISO 13485:2016 certification for its Lumee Oxygen Platform quality management system, a milestone in its European regulatory process.
• A proposed acquisition of G3 Vision Labs, Inc. is underway, subject to significant closing conditions including a $30 million financing requirement.
• The company's common stock is subject to potential delisting from Nasdaq, although it has regained compliance with certain listing requirements and is under mandatory panel monitor.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the company's continued going concern issues, significant net losses, and reliance on future financing, despite some operational improvements.

Positives

• Reduction in operating expenses: General and administrative expenses decreased by 78% and R&D expenses by 69% for the three months ended September 30, 2026, compared to the prior year.
• Secured ISO 13485:2016 certification for the Lumee Oxygen Platform, a key step in the European regulatory process.
• Continued access to financing through the Ascent PIPE Subscription Agreement and ELOC, providing potential liquidity.
• Successful forgiveness of the Paycheck Protection Program (PPP) loan, resulting in a gain on extinguishment of debt.
• Amendments to convertible notes and exchange agreements are being utilized to manage and settle outstanding debt obligations.

Negatives

• Substantial doubt about the company's ability to continue as a going concern persists, with a working capital deficit of $20.7 million as of September 30, 2026.
• Significant net losses continue: $17.2 million for the nine months ended September 30, 2026.
• The company's common stock faces potential delisting from Nasdaq, despite recent compliance efforts.
• The proposed acquisition of G3 Vision Labs is contingent on securing $30 million in financing and other conditions, with no guarantee of completion.
• The company has a history of recurring annual losses and negative operating cash flows.
• The conversion of Series A Preferred Stock and other convertible instruments could lead to substantial dilution for existing common stockholders.
• The company has limited cash reserves ($0.3 million as of September 30, 2026) and relies heavily on future financing.

Risks

• Substantial doubt about the company's ability to continue as a going concern within one year from the issuance date of the financial statements.
• The company may require additional financing to fund operations and commercialization efforts, and there is no assurance that such financing will be available on acceptable terms.
• Potential delisting from Nasdaq could adversely affect the liquidity and market price of its securities and its ability to raise capital.
• The proposed acquisition of G3 Vision Labs is subject to numerous conditions, including significant financing requirements, and may not be completed.
• Integration of G3, if acquired, presents challenges due to its different market focus and potential operational complexities.
• The conversion of Series A Preferred Stock and other convertible instruments could result in substantial dilution to existing stockholders.
• The company's ability to satisfy outstanding debt obligations depends on future financing and negotiations with creditors.
• Regulatory approvals for Lumee Oxygen (CE Mark) and Lumee Glucose are not guaranteed, and delays or failures could materially impact the business.

Future Outlook

The company expects to continue incurring losses and negative operating cash flows in the foreseeable future. It anticipates needing additional financing to fund operations, commercialization efforts, and further research and development. The success of the proposed G3 acquisition is contingent on securing significant financing and meeting other closing conditions. The company is also pursuing renewed CE Mark certification for its Lumee Oxygen Platform.

Management Comments

• Management expects to continue to incur additional substantial losses in the foreseeable future as a result of research and development activities.
• There can be no assurance that the Company will obtain additional financing under either agreement or that sufficient funds will be available to support its ongoing operations, product research and development, and commercialization activities.
• There can be no assurance regarding the timing or successful completion of the remaining regulatory requirements or the issuance of the CE Mark.
• There can be no assurance that we will maintain compliance with Nasdaqs continued listing standards.
• We expect that we will require additional financing to fund our operations and planned growth.

Industry Context

StockSavvy.ai notes that Profusa operates in the highly competitive and capital-intensive medical technology sector, specifically focusing on biosensing solutions. The company's challenges with regulatory approvals (CE Mark, FDA), Nasdaq listing compliance, and significant ongoing losses are common in this industry, where long development cycles and substantial R&D investment are required before commercialization and profitability can be achieved. The company's strategic moves, such as the potential G3 acquisition and various debt/equity financing arrangements, reflect typical industry strategies for growth and survival.

Comparison to Industry Standards

• Companies in the medical technology sector often face lengthy and costly regulatory approval processes, similar to Profusa's pursuit of CE Mark certification for its Lumee Oxygen Platform.
• The need for significant ongoing financing is characteristic of early-stage medical device companies, where substantial R&D and clinical trial costs precede revenue generation.
• Challenges with Nasdaq listing requirements, such as minimum bid price, are not uncommon for smaller, development-stage companies, and often necessitate reverse stock splits or other corporate actions to maintain compliance.
• The strategy of settling debt or compensation with equity is a common practice for companies facing liquidity constraints, though it can lead to significant dilution for existing shareholders.

Management Changes

Legal Proceedings

• The company is not currently subject to any material legal proceedings.
• A notice of entry of judgment was received in December 2025 in connection with litigation brought by a vendor, ruled in favor of the vendor, with approximately $0.1 million accrued.
• A demand letter was received in February 2026 from counsel for a former employee for unpaid wages of approximately $0.2 million, including statutory penalties, which has been accrued.

Related Party Transactions

• The company has outstanding convertible notes held by Tasly (shareholder) and NVAC (shareholder), valued at $2.7 million and $1.0 million respectively as of September 30, 2026.
• Promissory notes held by founders were $0 as of September 30, 2026, compared to $0.4 million as of December 31, 2025.
• Due to Related Party (NVAC) was $0 as of September 30, 2026, compared to $41,000 as of December 31, 2025, related to an administrative service fee.

Stakeholder Impact

• Shareholders face potential dilution from the conversion of Series A Preferred Stock and other convertible instruments, as well as the risk of delisting from Nasdaq.
• Creditors and noteholders are involved in debt exchange agreements and amendments, indicating active management of outstanding obligations.
• Employees may be impacted by the reduction in force, though specific details on severance or bonuses are not fully detailed in this section.
• Potential acquirers of G3 Vision Labs (if the acquisition closes) will be subject to the terms of the acquisition and integration process.

Next Steps

• Continue efforts to obtain renewed CE Mark certification for the Lumee Oxygen Platform.
• Complete the proposed acquisition of G3 Vision Labs, subject to financing and other closing conditions.
• Continue to manage outstanding debt obligations through conversions, exchanges, and potential refinancing.
• Seek additional equity or debt financing to support ongoing operations and commercialization efforts.
• Maintain compliance with Nasdaq's continued listing standards.
• Pursue stockholder approval for the conversion of Series A Non-Voting Convertible Preferred Stock.

Key Dates

Recommendation

While Profusa is making strategic moves to manage its debt and pursue growth opportunities like the G3 acquisition, the persistent going concern issues, significant net losses, and Nasdaq delisting risk present considerable headwinds. The company's ability to secure necessary financing and achieve regulatory milestones remains critical. For these reasons, a 'hold' recommendation is appropriate, pending clearer signs of financial stabilization and successful execution of its strategic initiatives.

Keywords

Profusa, 10-Q, Series A Preferred Stock, Convertible Notes, Financing, Going Concern, Nasdaq Listing, G3 Acquisition